September 2016
Volume 57, Issue 12
Free
ARVO Annual Meeting Abstract  |   September 2016
A comparison of expected dwell times and dose variations for neovascular age-related macular degeneration (n-AMD) patients treated with an episcleral brachytherapy device.
Kamaljit S Balaggan; Russell J. Hamiliton; Mary E. Drew; Praveen J Patel; Daren Hanumunthadu; Reid Schindler; Marie Restori; Tomas Ilgins; Meghan McGovern; Laurence Marsteller
Author Affiliations & Notes
  • Kamaljit S Balaggan
    Moorfields Eye Hospital, London, United Kingdom
    Ophthalmology, Wolverhampton Eye Infirmary, Wolverhampton, United Kingdom
  • Russell J. Hamiliton
    Radiation Oncology, University of Arizona, Tucson, Arizona, United States
  • Mary E. Drew
    Salutaris Medical Devices, Inc., Tucson, Arizona, United States
  • Praveen J Patel
    NIHR Biomedical Research Centre at Moorfields and UCL, London, United Kingdom
  • Daren Hanumunthadu
    NIHR Biomedical Research Centre at Moorfields and UCL, London, United Kingdom
  • Reid Schindler
    Retina Specialists of Southern Arizona, Tucson, Arizona, United States
  • Marie Restori
    Moorfields Eye Hospital, London, United Kingdom
  • Tomas Ilgins
    NIHR Biomedical Research Centre at Moorfields and UCL, London, United Kingdom
  • Meghan McGovern
    Salutaris Medical Devices, Inc., Tucson, Arizona, United States
  • Laurence Marsteller
    Salutaris Medical Devices, Inc., Tucson, Arizona, United States
  • Footnotes
    Commercial Relationships   Kamaljit Balaggan, DORC (R), Novartis (R), SalutarisMD (C); Russell Hamiliton, Salutaris Medical Devices, Inc. (I), Salutaris Medical Devices, Inc. (P); Mary Drew, Salutaris Medical Devices, Inc. (E); Praveen Patel, Bayer (C), Heidelberg Inc (F), Novartis (C), Salutaris Medical Devices Inc (R), Thrombogenics NV (C), Thrombogenics NV (F), Topcon Inc (F); Daren Hanumunthadu, Salutaris Medical Devices, Inc. (R); Reid Schindler, Salutaris Medical Devices, Inc. (I), Salutaris Medical Devices, Inc. (F); Marie Restori, None; Tomas Ilgins, None; Meghan McGovern, Salutaris Medical Devices, Inc. (C); Laurence Marsteller, Salutaris Medical Devices, Inc. (S), Salutaris Medical Devices, Inc. (E), Salutaris Medical Devices, Inc. (I), Salutaris Medical Devices, Inc. (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4426. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      A comparison of expected dwell times and dose variations for neovascular age-related macular degeneration (n-AMD) patients treated with an episcleral brachytherapy device.
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Kamaljit S Balaggan, Russell J. Hamiliton, Mary E. Drew, Praveen J Patel, Daren Hanumunthadu, Reid Schindler, Marie Restori, Tomas Ilgins, Meghan McGovern, Laurence Marsteller; A comparison of expected dwell times and dose variations for neovascular age-related macular degeneration (n-AMD) patients treated with an episcleral brachytherapy device.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4426. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : To evaluate variations in dwell times and doses expected when using an episcleral brachytherapy device for treatment of n-AMD based on Optical Coherence Tomography and Ocular Ultrasound imaging modalities. To determine if a mean target depth is appropriate for all patients receiving episcleral brachytherapy.

Methods : Data from 40 eyes from 40 subjects with known n-AMD was acquired through the Distance of Choroid Study (DOCS) conducted at Moorfields Eye Hospital. The purpose of DOCS was to determine the repeatability and limits of agreement of existing imaging modalities for the determination of retinal, choroidal and scleral thickness at the fovea and choroidal neovascularization (CNV) lesion in vivo. Each subject underwent EDI SD-OCT, SS-OCT and Ocular Ultrasound (O-US). Using the percentage depth dose for a Sr-90 episcleral brachytherapy device, dwell times and doses delivered are computed to determine the expected variations of each subject.

Results : The mean distance to target depth and the 95% confidence interval (CI) determined by combining O-US with SD-OCT were 1326 (956,1696)mm and with SS-OCT were 1332 (970,1693)mm. The calculated corresponding mean dwell times and 95% (CI) were 334 (223, 445)s and 335 (226, 445)s for SD-OCT and SS-OCT determined depths, respectively. The patient population average target depth for treatment planning results in dose variations of +/-33% over the 95% CI.

Conclusions : The mean dwell times showed no significant difference between SD-OCT and SS-OCT. Each patient should have individualized imaging studies to determine the target depth.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

The apex dose for each patient found using the dwell time calculated based on the population average depth. The solid line is the intended prescription dose of 24Gy and the dotted lines are ±15% variations above and below this. The apex dose differs by more than 15% for 40% (16/40) of the patients if the population average depth is used for the dwell time calculation.
View OriginalDownload Slide

The apex dose for each patient found using the dwell time calculated based on the population average depth. The solid line is the intended prescription dose of 24Gy and the dotted lines are ±15% variations above and below this. The apex dose differs by more than 15% for 40% (16/40) of the patients if the population average depth is used for the dwell time calculation.

The apex dose for each patient found using the dwell time calculated based on the population average depth. The solid line is the intended prescription dose of 24Gy and the dotted lines are ±15% variations above and below this. The apex dose differs by more than 15% for 40% (16/40) of the patients if the population average depth is used for the dwell time calculation.

The apex dose for each patient found using the dwell time calculated based on the population average depth. The solid line is the intended prescription dose of 24Gy and the dotted lines are ±15% variations above and below this. The apex dose differs by more than 15% for 40% (16/40) of the patients if the population average depth is used for the dwell time calculation.
View OriginalDownload Slide
 
Depth dose curve along a line through the center of the applicator and perpendicular to it. The dose changes rapidly with depth. When the prescription dose (24Gy) is delivered at a depth equal to the mean apex depth of the patients in our study (1.326mm), the doses at the apex depths within the 95% confidence interval of our patients, 0.956mm to 1.696mm, range from 33.6Gy to 17.1Gy.
View OriginalDownload Slide

Depth dose curve along a line through the center of the applicator and perpendicular to it. The dose changes rapidly with depth. When the prescription dose (24Gy) is delivered at a depth equal to the mean apex depth of the patients in our study (1.326mm), the doses at the apex depths within the 95% confidence interval of our patients, 0.956mm to 1.696mm, range from 33.6Gy to 17.1Gy.

Depth dose curve along a line through the center of the applicator and perpendicular to it. The dose changes rapidly with depth. When the prescription dose (24Gy) is delivered at a depth equal to the mean apex depth of the patients in our study (1.326mm), the doses at the apex depths within the 95% confidence interval of our patients, 0.956mm to 1.696mm, range from 33.6Gy to 17.1Gy.

Depth dose curve along a line through the center of the applicator and perpendicular to it. The dose changes rapidly with depth. When the prescription dose (24Gy) is delivered at a depth equal to the mean apex depth of the patients in our study (1.326mm), the doses at the apex depths within the 95% confidence interval of our patients, 0.956mm to 1.696mm, range from 33.6Gy to 17.1Gy.
View OriginalDownload Slide

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2015 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept